HomeAI · summaries
Storia in 2 fonti
Merck, Gilead score in effort to develop the first weekly HIV pill
A combination of Merck’s islatravir and Gilead’s lenacapavir has
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
fiercepharma.com
ADA: Novo's Wegovy pill reaches new GLP-1 patients with impressive 3M prescription milestone
For Novo Nordisk, the launch of the company’s highly anticipated Wegovy pill at the start of the year—representing the first oral GLP-1 for obesity—marked an opportunity to…
- ·
biopharmadive.com
Merck, Gilead report mixed outcomes in key lung cancer, HIV studies
Trodelvy's latest setback carries implications for a newly important Merck drug, while the success of a once-weekly HIV tablet could boost Gilead's main business.
- ·
As Gilead's Trodelvy stumbles in first-line lung cancer, all eyes turn to Merck, AZ and Daiichi rivals
Following another phase 3 failure for Gilead Sciences’ Trodelvy, the race to bring a TROP2 antibody-drug conjugate (ADC) to patients with first-line non-small cell lung cancer…
- ·
Merck, Gilead score in effort to develop the first weekly HIV pill
A combination of Merck’s islatravir and Gilead’s lenacapavir has